Navigation Links
Perrigo Announces FDA Tentative Approval for Ibuprofen PM
Date:10/29/2008

ALLEGAN, Mich., Oct. 29 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received tentative approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for over-the-counter (OTC) Ibuprofen and Diphenhydramine Citrate Tablets, 200/38 mg. The national brand's exclusivity ends prior to the end of the calendar year.

The product will be marketed under store brand labels and is comparable to Wyeth Consumer Healthcare's Advil(R) PM tablets, 200/38 mg, indicated as a pain reliever (NSAID)/nighttime sleep-aid. Estimated brand sales for the product for the last 12 months ending September 28, 2008 were $70 million.

Perrigo's Chairman and CEO Joseph C. Papa stated, "This is another example of Perrigo's investment in new products making quality healthcare more affordable to American consumers. This is an important addition to our portfolio of products that saves the consumer of our OTC healthcare products approximately $1 billion annually when compared to the higher priced national brands."

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes OTC and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 28, 2008, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
2. Perrigo Company To Present at the Merrill Lynch Global Pharmaceutical Conference
3. Perrigo Begins Shipments of Famotidine Complete to Customers Nationwide
4. Perrigo Company Announces Appointment of New Board Member
5. Perrigo Company to Present at The Oppenheimer & Co. Inc. 8th Annual Consumer Growth Conference
6. Perrigo Announces Approval for Rx Cetirizine Syrup
7. Perrigo Confirms Filing for Generic Version of VANOS(R)
8. Perrigo Company Announces Collaborative Agreement for Generic Topical Products With Pentech
9. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
10. Perrigo Reports Record Sales and Earnings for Third Quarter Fiscal 2008
11. Perrigo Company Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... ... May 04, 2016 , ... All-Star Insurance of Northeast ... the people of their local community. The agency pledges to select a new ... hope is to bring awareness to important local causes with fundraising and other ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... teamed up with one of the top website design companies to create a ... legal articles related to the law firm's main practice areas. These practice areas ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nordic Naturals announces another breakthrough ... health. This synergistic combination of omega-3 fatty acids and potent antioxidants contains 1000 ... reduced glutathione and 200 mg of N-Acetylcysteine (NAC). , Each nutrient plays ...
(Date:5/4/2016)... ... 04, 2016 , ... Natalie Jill is a well respected lifestyle ... of the launch of her new book: Natalie Jill’s 7 Day Jump Start: Unprocess ... to jump start a new healthy lifestyle featuring simple recipes using MitoXcell’s raw cacao ...
(Date:5/4/2016)... ... May 04, 2016 , ... Bayco Products has ... (6.7 inch) dual-light flashlights in models NSP-9842XL and NSR-9844XL . , First ... at $59.95) uses 2 included CR-123 batteries to produce up to 650 lumens ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... , May 3, 2016  Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product ... Photo - http://photos.prnewswire.com/prnh/20160503/362921 ... ... ... ...
(Date:5/3/2016)... LAKE OSWEGO, Ore. , May 3, 2016 /PRNewswire/ ... about the importance of extending care beyond the implant ... Scientific Sessions, May 4-7 in San Francisco ... tasked with continually delivering the highest quality of patient ... ensuring patients are cared for each and every tomorrow," ...
(Date:5/3/2016)... -- Intec Pharma Ltd. (NASDAQ: ... announced the appointment of Pnina Strauss-Levy as ... Strauss-Levy has 15 years of experience in clinical research ... record, having supported the advancement of several products through ... the United States and ...
Breaking Medicine Technology: